With most patients with myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDS) experiencing long-term, chronic disease, it’s important to discuss their priorities and set up the relationship with their providers upfront, explained Jennifer Vaughn, MD, assistant professor in the division of hematology at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute.